1.13
0.00%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About INmune Bio
Its shares trade under the ticker INMB. It has been listed since 4 February 2019. In the fiscal year to 31 December 2025, it reported revenue of $50,000 and a net loss of $45.9m. At that date it held total assets of $32.4m and shareholders' equity of $23.5m.
INmune Bio, Inc. focuses on controlling components of the immune system to activate an immune response against cancer and Alzheimer’s disease. The company is headquartered in La Jolla, California. The company went IPO on 2019-02-04. The firm is focused on developing strategies for oncology that focus on re-engineering and harnessing the innate immune system to treat the patient’s cancer. The Company’s product candidates (INMB) target cells of the innate immune system that include natural killer cells (NK cells) and myeloid derived suppressor cells, (MDSC cells). The NK cell of the innate immune system has two primary functions, such as to kill virally infected cells and to kill cancer cells. Its INB03 is a protein biologic that has beneficial effects in patients with cancer. Its initial focus is on its ability to inhibit proliferation and function of myeloid-derived suppressor cells (MDSC).
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 4 Feb 2019
- Employees
- 5
- Website
- inmunebio.com ↗
- Head office
- 225 NE MIZNER BLVD, SUITE 640, BOCA RATON, FL, 33432
- Incorporated in
- NV
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. David MossPresident, Chief Executive Officer$2.7m
- Mr. Cory EllspermannChief Financial Officer
- Prof. Mark LowdellChief Scientific Officer$1.8m
- Ms. Marcia AllenIndependent Director$293,598
- Mr. J. Kelly GanjeiIndependent Director$293,598
- Mr. Scott JudaIndependent Director$293,598
- Mr. Timothy SchroederIndependent Director$293,598
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 31
- Environment
- 34
- Social
- 25
- Governance
- 33
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- INmune Bio Inc possesses several key strengths that contribute to its competitive advantage and potential success in the market. These include:
Weaknesses
- Despite its strengths, INmune Bio Inc faces certain weaknesses and challenges that could potentially hinder its growth and performance. These include:
Opportunities
- INmune Bio Inc can capitalize on various opportunities within the industry to fuel its growth and establish a stronger market presence. These opportunities include:
Threats
- INmune Bio Inc must also be aware of potential threats and external factors that could impact its business operations and market standing. These threats include:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.